A traditional Japanese medicine mitigates TNBS-induced colitis in rats
A traditional Japanese medicine mitigates TNBS-induced colitis in rats
复制标题
DOI：
10.1080/00365520600575704
复制
发表时间：
2006-10-01
影响因子：
1.9
通讯作者：
Takahashi, Ryoki
中科院分区：
文献类型：
--
作者：
Fukuda, Yoshihiro;Tao, Yang;Takahashi, Ryoki
目标。饮食习惯的差异可能是炎症性肠病在日本的发病率低于西方国家的原因之一。我们研究了一种以米曲霉曲曲为基础的传统日本药物（强Wakamto (R)）是否会对实验性结肠炎大鼠产生任何影响。材料和方法。采用三硝基苯磺酸（TNBS）和乙醇灌肠诱导结肠炎。在诱导结肠炎前和诱导结肠炎后分别给予强Wakamto 28天和7天，并评价该药的效果。结果。5%强Wakamto治疗改善了体重减轻，增加了结肠重量，显著降低了结肠黏膜的组织学损伤评分。强Wakamto可改善TNBS灌肠后粪便中乳酸杆菌、超氧化物歧化酶活性和锌浓度的降低以及结肠组织中IL-1 β表达的升高。目前的体外研究表明，服用强Wakamto可以阻止人巨噬细胞中脂多糖诱导的tnf - α产生。结论。口服强Wakamto可减轻TNBS灌肠引起的实验性炎症性肠病。这种有益效果似乎可归因于平衡微生物群、对肠道巨噬细胞的免疫调节作用和增强结肠组织抗超氧化物活性的综合作用。
Objective. Differences in dietary habits may be one of the reasons that the incidence of inflammatory bowel disease has remained lower in Japan than in Western countries. We investigated whether a traditional Japanese medicine (Strong Wakamto (R)), based on Aspergillus oryzae koji, would exert any effect on experimental colitis in rats. Material and methods. Colitis was induced using an enema of trinitrobenzene sulfonic acid (TNBS) and ethanol. Strong Wakamto was administered for 28 days before induction of colitis and for 7 days thereafter, and the effect of this medicine was evaluated. Results. Treatment with 5% Strong Wakamto improved loss of body-weight, increased colon weight and significantly decreased the histological damage score for colon mucosa. Decreases in faecal Lactobacillus sp., superoxide dismutase activity and zinc concentrations, and the increased IL-1 beta expression in colonic tissue after TNBS enema were improved when Strong Wakamto was given. The present in vitro studies indicate that administration of Strong Wakamto prevents lipopolysaccharide-induced TNF-alpha production in human macrophages. Conclusions. Oral administration of Strong Wakamto mitigates experimental inflammatory bowel disease induced by TNBS enema in rats. The beneficial effects seem attributable to a combination of balancing microflora, immunomodulatory effects on gut macrophages, and enhancement of anti-superoxide activity in colonic tissues.